CCT6A suppresses SMAD2 and promotes prometastatic TGF-[beta] signaling

MLA

Ying, Zhe, et al. “CCT6A Suppresses SMAD2 and Promotes Prometastatic TGF-[Beta] Signaling.” Journal of Clinical Investigation, vol. 127, no. 5, May 2017, p. 1725. EBSCOhost, https://doi.org/10.1172/JCI90439.

APA

Ying, Z., Tian, H., Li, Y., Lian, R., Li, W., Wu, S., Zhang, H.-Z., Wu, J., Liu, L., Song, J., Guan, H., Cai, J., Zhu, X., Li, J., & Li, M. (2017). CCT6A suppresses SMAD2 and promotes prometastatic TGF-[beta] signaling. Journal of Clinical Investigation, 127(5), 1725. https://doi.org/10.1172/JCI90439.

Chicago

Ying, Zhe, Han Tian, Yun Li, Rong Lian, Wei Li, Shanshan Wu, Hui-Zhong Zhang, et al. 2017. “CCT6A Suppresses SMAD2 and Promotes Prometastatic TGF-[Beta] Signaling.” Journal of Clinical Investigation 127 (5): 1725. doi:10.1172/JCI90439.